Navigation Links
Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
Date:9/13/2010

PRINCETON, N.J., Sept. 13 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, announced today that its President and Chief Executive Officer Christopher J. Schaber, Ph.D. will present a company overview highlighting recent developments at the Rodman & Renshaw 12th Annual Healthcare Conference in New York City.  The presentation will take place on Wednesday, September 15, 2010 at 10:00AM EDT in the Spellman Salon (5th Floor) of the New York Palace Hotel.

The Soligenix presentation will be webcast live and archived for later replay. To access the webcast, please visit the Company's "Investor" page at www.soligenix.com.  A replay of the presentation will be archived for 30 days after the conference at the same location.

About Soligenix, Inc.

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host-Disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD and an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Soligenix is also conducting an NIH-supported Phase 1/2 clinical trial of SGX201 in the prevention of acute radiation enteritis. Additionally, Soligenix has a Lipid Polymer Micelle (LPM™) drug delivery technology for the oral
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... YORK and KISSING, Germany ... and distributor of a single use and computer-assisted ("robotic") ... (Homi) Shamir , a worldwide recognized medical device executive, ... Mr. Shamir is a highly respected global ... recent assignment he served as President and Chief Executive ...
(Date:7/30/2014)... 30, 2014  DigiPath, Inc. (OTCBB and OTCQB: DIGP), ... the cannabis testing and education markets, announced today that ... affairs not previously disclosed or, to its knowledge, any ... action. "We have noticed unusual price and ... trading days," said Steve Barbee , CEO of ...
(Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics Inc. ... treatments based on its expertise in opioid antagonists, ... commitment from a prominent international research and development ... on promoting innovative research-based initiatives, including those addressing ... spray for the delivery of naloxone that could ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3DigiPath No New Corporate Developments 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ), ... and gastroenterology markets, today announced that it has entered ... a new Phase II development product. The Company has ... Injection and is evaluating the product for the treatment ...
... Inc. (NYSE: CRY ), an implantable biological ... that 2011 first quarter financial results will be released ... Company will hold a teleconference call and live webcast ... followed by a question and answer session hosted by ...
Cached Medicine Technology:Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 4CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results 2
(Date:7/30/2014)... Imprivata ® (NYSE: IMPR), ... secure communications solutions for the healthcare industry, today ... most widely selected single sign-on (SSO) solution amongst ... medical records (EMR) systems with a 51 percent ... in the last 12 months), according to HIMSS ...
(Date:7/30/2014)... obese people have a genetic mutation that seems to ... they see food, researchers report. Gaining a better ... and gratification at the sight of high-calorie foods like ... the scientists suggested. More than one-third of U.S. ... a combination of overeating, a lack of physical activity ...
(Date:7/30/2014)... Orange, NJ. July 30, 2014. A new network of ... NIH Stroke Trials Network (NIH StrokeNet) is working ... the U.S. Despite advances of the last two ... year, stroke causes death or disability for 795,000 Americans. ... aging of the population. , To accelerate the ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased ... Chack will serve as chair. The board was voted ... Learning Conference in Houston, Texas July 10-12. , ... of us. From the rollout of the first EDNF ... Baltimore Medical Center to our September physicians conference to ...
(Date:7/30/2014)... As the controversy surrounding the use ... continues to grow, Bernstein Liebhard LLP notes that another ... a ban on uterine morcellation. According to a report ... leiomyosarcoma following a hysterectomy that involved the use of ... the aggressive cancer had progressed to Stage 4. Ms. ...
Breaking Medicine News(10 mins):Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Gene Mutation May Make Food More Tempting 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4
... , , , BOISE, Idaho, Dec. 28 The research shows, ... bulge becomes a main priority for those setting New Year resolutions ... war; individuals must be prepared to make lifestyle changes starting with ... Light offer two ways to indulge while working off and managing ...
... , ... Absolutely Public Relations reviews 2009 key media placement results, plus celebrates client and ... anniversary in business, representing the Colorado Cleantech Industry Association, Bell Aquaculture, Colorado BioScience ... , ...
... , WASHINGTON, Dec. 28 CAQH® announced today that ... are the first national health plans to earn certification ... on Operating Rules for Information Exchange® (CORE) Phase II ... in the ongoing development of the CORE rules, which ...
... 28, 2009 -- Children regularly exposed to tobacco smoke ... in adulthood. This finding by researchers at Columbia University,s ... may not recover completely from the effects of early-life ... in the December 2009 American Journal of Epidemiology ...
... , ASHBURN, Va., Dec. ... data capture and enterprise search solutions , today ... France, has selected the company,s Brainware Distiller(TM) solution to automate ... 150 countries and processes hundreds of thousands of invoices and ...
... ... Jack Canfield, Dr. Joe Vitale & Marci Shimoff, Jennifer Nicole Lee is ... and enlightens audiences worldwide with her highly anticipated book "The Mind, Body ... story who has become one of the world,s most accomplished fitness experts. ...
Cached Medicine News:Health News:Make Your 2010 Resolution and Chill Out with Crystal Light Frozen Treats 2Health News:Denver Public Relations Consulting Firm, Absolutely Public Relations, Recaps 2009 Key Media Placement Results, Plus Client and Company Milestones 2Health News:Denver Public Relations Consulting Firm, Absolutely Public Relations, Recaps 2009 Key Media Placement Results, Plus Client and Company Milestones 3Health News:Denver Public Relations Consulting Firm, Absolutely Public Relations, Recaps 2009 Key Media Placement Results, Plus Client and Company Milestones 4Health News:Aetna and WellPoint Achieve CORE Phase II Certification 2Health News:Aetna and WellPoint Achieve CORE Phase II Certification 3Health News:Exposure to tobacco smoke in childhood home associated with early emphysema in adulthood 2Health News:bioMerieux Selects Brainware to Automate Accounts Payable 2Health News:bioMerieux Selects Brainware to Automate Accounts Payable 3Health News:Fitness Celebrity Jennifer Nicole Lee Reveals her Revolutionary Weight Loss Principles in 'The Mind, Body, and Soul Diet' Book 2Health News:Fitness Celebrity Jennifer Nicole Lee Reveals her Revolutionary Weight Loss Principles in 'The Mind, Body, and Soul Diet' Book 3Health News:Fitness Celebrity Jennifer Nicole Lee Reveals her Revolutionary Weight Loss Principles in 'The Mind, Body, and Soul Diet' Book 4
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Silicone Oil Cannula; 16g (1.40) x 8mm....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
...
Medicine Products: